Sign up to save your podcasts
Or
Share Experts Talk AML #7: ELN Recommendations & New Classification of AML
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Experts Talk AML #7: ELN Recommendations & New Classification of AML
A discussion between Dr. Daniel A. Pollyea and Dr. Brian Leber (November 2022)
Dr. Pollyea and Dr. Leber examine the new hierarchical AML classification algorithm proposed by the ELN expert panel and discuss its impact on the routine practice and design of future clinical trials in AML. They scrutinize diagnostic and prognostic features, from blast counts and genetic abnormalities to cytogenetic characteristics and diagnostic qualifiers. Finally, they provide insight into how various decision-makers in the US and Canada might react when approving treatment eligibility for patients who, due to the new classification, meet eligibility criteria that were not previously met.
The algorithm discussed is available on the podcast hosting site at www.hematologypodcasts.ca
Daniel A. Pollyea, MD, MS, Associate Professor of Medicine, Clinical Director of Leukemia Services, Robert H. Allen MD Chair in Hematology Research, Division of Hematology, University of Colorado, School of Medicine
Brian Leber, MD, BSc, MDCM, FRCPC, Professor of Medicine (Hematology), McMaster University, Attending Physician and Hematologist. Head, Leukemia Group. Co-Director, Cellular Therapy Programme (formerly Stem Cell Transplant Programme) Director, Molecular Hematology Laboratory, Juravinski Hospital and Cancer Centre, Hamilton Health Sciences
This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.
View all episodes
By Various Topics on AML and CLL ManagementA discussion between Dr. Daniel A. Pollyea and Dr. Brian Leber (November 2022)
Dr. Pollyea and Dr. Leber examine the new hierarchical AML classification algorithm proposed by the ELN expert panel and discuss its impact on the routine practice and design of future clinical trials in AML. They scrutinize diagnostic and prognostic features, from blast counts and genetic abnormalities to cytogenetic characteristics and diagnostic qualifiers. Finally, they provide insight into how various decision-makers in the US and Canada might react when approving treatment eligibility for patients who, due to the new classification, meet eligibility criteria that were not previously met.
The algorithm discussed is available on the podcast hosting site at www.hematologypodcasts.ca
Daniel A. Pollyea, MD, MS, Associate Professor of Medicine, Clinical Director of Leukemia Services, Robert H. Allen MD Chair in Hematology Research, Division of Hematology, University of Colorado, School of Medicine
Brian Leber, MD, BSc, MDCM, FRCPC, Professor of Medicine (Hematology), McMaster University, Attending Physician and Hematologist. Head, Leukemia Group. Co-Director, Cellular Therapy Programme (formerly Stem Cell Transplant Programme) Director, Molecular Hematology Laboratory, Juravinski Hospital and Cancer Centre, Hamilton Health Sciences
This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.